TrialThe Lancet. Oncology2019

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

Eleftherios P Mamounas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.